Alzheimer’s impact is a societal and economic issue, health advocate says

* This article originally appeared on Cleveland.com CLEVELAND, Ohio -- Alzheimer’s disease afflicts nearly 6 million people in the United States, and sadly affects the many more millions of people who love them. Yet the chairman and co-founder of UsAgainstAlzheimer’s believes that most people -- especially those who could help make a difference -- don’t grasp the overall scope and impact of the brain disorder, which progressively destroys thinking and memory skills. “Political leaders here and abroad are not responding at the scope and scale needed to beat back this disease,” says George Vradenburg, an Oberlin College graduate who, with

New hope for patients with Alzheimer's: How one family is fighting the disease

*This article originally appeared on Today.com Like his mother Virginia O'Brien before him, Greg O’Brien is battling Alzheimer’s disease with all his might. O'Brien's mother did everything she could to stave off the disease as she cared for her cancer-stricken, wheelchair-bound husband. And she did somehow manage to keep things going until her husband, O'Brien's father, died from prostate cancer. It was from watching his mother live with Alzheimer’s that allowed O'Brien to recognize the signs in himself and prompted him to see a neurologist at age 59. Brain scans that revealed he had Alzheimer’s, too. Shortly after his own

Forming Your “Circle of Help”

The best way to defeat Alzheimer’s is to come together and gang up on the disease.

Growing Our Voices: Let’s Talk About Dementia

1994: President Ronald Reagan penned his now famous letter to the American public announcing that he was in the early stages of Alzheimer’s disease. The same year, m y dad , at 81, had just been diagnosed with “memory problems”; my son Mike was a sophomore in high school; and I was three years into a new marriage and at the top of my Human Resources career. Three years later my husband Richard, at 57, was diagnosed with Mild C ognitive I mpairment . Dad died in 2001 from what I later learned was vascular dementia and Richard in 2012

“A Devil of a Disease”: The Current Alzheimer’s Pipeline

This article was originally published by BioSpace on August 7, 2019. By Mark Terry As anyone following Alzheimer’s research knows, drug development for the disease has been a wasteland of failed clinical trials with literally billions of dollars thrown at drugs that have proved ineffective at preventing or halting the disease. In March 2019, in what many felt was a turning point for the industry, Cambridge, Massachusetts-based Biogen and its collaboration partner, Tokyo-based Eisai, announced they were discontinuing the global Phase III clinical trials, ENGAGE and EMERGE, of aducanumab in patients with mild cognitive impairment from Alzheimer’s and mild Alzheimer’s